Core Viewpoint - The Hong Kong biotechnology sector is experiencing a significant upward trend, with notable gains in various stocks, indicating positive market sentiment in the industry [1] Group 1: Stock Performance - Nocare Biopharma (09969.HK) has seen an increase of over 4% [1] - Other companies such as Zai Lab (09688.HK), WuXi AppTec (02359.HK), WuXi Biologics (02269.HK), and Innovent Biologics (02696.HK) are also witnessing upward movement in their stock prices [1]

（文章来源：每日经济新闻） 每经AI快讯，2月5日，港股生物医药板块震荡走高，诺诚健华(09969.HK)涨超4%，再鼎医药 (09688.HK)、药明康德(02359.HK)、药明生物(02269.HK)、复宏汉霖(02696.HK)等个股跟涨。 ...

Core Insights - The report highlights the release of the "Low Altitude Economic Standard System Construction Guide (2025 Edition)", marking a significant step in the regulation and development of the low altitude economy in China [13]. Group 1: Industry Dynamics - The Guangdong provincial government has set development goals for the low altitude economy in its 2026 work report, indicating a commitment to advancing this sector [13]. Group 2: Policy Developments - The "Low Altitude Economic Standard System Construction Guide (2025 Edition)" is the first comprehensive standard document in China's low altitude economy sector, aimed at transitioning the industry from "chaotic growth" to "regulated and scaled development" [13]. Group 3: Company Developments - WoFei ChangKong has completed a new round of financing amounting to nearly 1 billion yuan, setting a record for the largest single financing in the low altitude economy at the start of 2026. The funds will be used for the certification of the AE200 series, the production of a global headquarters, and the construction of a low altitude travel business model [12].

上天天基金APP搜索777注册即可领500元券包，优选基金10元起投！限量发放！先到先得！ 当地时间2月4日，美股三大股指收盘涨跌不一，在多家科技权重持续回调的压力下，纳指连续第二 天跌超1%。 因最新财报中一季度指引不及预期，AMD大跌超17%，美光科技跌逾9%，特斯拉跌近4%，英伟 达跌超3%。 受美国"小非农"就业数据疲软、AI芯片需求波动及美联储降息节奏不确定性影响，投资者对成长股 估值与经济韧性信心承压，风险偏好趋于谨慎。 纳指两连跌 AMD大跌超17% 当地时间2月4日，美股三大股指收盘涨跌不一。道指涨0.53%报49501.3点，标普500指数跌 0.51%报6882.72点，纳指跌1.51%报22904.58点。 大型科技股多数下跌，万得美国科技七巨头指数下跌1.32%。个股方面，特斯拉跌近4%，脸书、 英伟达跌超3%，亚马逊跌逾2%，谷歌跌近2%，苹果涨超2%，微软涨0.72%。 芯片股表现疲软，费城半导体指数跌4.36%。其中，超威半导体（AMD）跌超17%。 | 200.190+ 最高 218.580 今 开 215.000 | | --- | | -41.920-17.31% 最低 1 ...

Summary of Key Points Core Viewpoint - JPMorgan Chase has increased its stake in Zai Lab Limited (09688) by acquiring 1,920,096 shares at a price of HKD 13.3426 per share, totaling approximately HKD 25.6191 million, resulting in a new holding of about 56,470,300 shares, which represents a 5.04% ownership stake [1][3]. Group 1 - JPMorgan Chase's acquisition of shares indicates a strategic investment in Zai Lab Limited [1][3]. - The total amount spent on the share purchase was approximately HKD 25.6191 million [1][3]. - Following the purchase, JPMorgan's total shareholding in Zai Lab is now approximately 56,470,300 shares [1][3].

Core Viewpoint - Zai Ding Pharmaceutical (09688) announced the issuance of new shares to fulfill stock awards and options under various equity incentive plans [1] Group 1: Share Issuance Details - On February 4, 2026, the company will issue 3.8891 million new shares held by a trustee to fulfill stock awards granted under the 2017, 2022, and 2024 equity incentive plans [1] - Additionally, on the same date, the company will issue 4.6109 million new shares held by a trustee to fulfill stock awards and options granted to executive directors under the 2015, 2017, 2022, and 2024 equity incentive plans [1]

Core Viewpoint - Zai Ding Pharmaceutical (09688) announced the issuance of new shares to fulfill stock incentive plans and options granted to executive directors [1] Group 1: Share Issuance Details - On February 4, 2026, the company will issue 3.8891 million new shares held by a trustee to fulfill the stock awards granted under the 2017, 2022, and 2024 equity incentive plans [1] - Additionally, on the same date, the company will issue 4.6109 million new shares held by a trustee to fulfill the stock awards and options granted to executive directors under the 2015, 2017, 2022, and 2024 equity incentive plans [1]

Group 1 - JPMorgan Chase & Co. increased its stake in Zai Lab Limited (09688.HK) by purchasing 1.9201 million shares at an average price of HKD 13.3426 per share, totaling approximately HKD 25.619 million [1] - Following this acquisition, JPMorgan's total holdings in Zai Lab rose to 56.4703 million shares, increasing its ownership percentage from 4.87% to 5.04% [1]

| 2). 就根據股份計劃授予發行人的董事的股份獎勵或期權而發行新股或轉 | 4,610,920 | 0.41 % | HKD | 0 | | | --- | --- | --- | --- | --- | --- | | 讓庫存股份 - 涉及新股 | | | | | | | 發行新股，由受託人持有，以兌現按先前披露的條款歸屬/行使根據 | | | | | | | 2015，2017，2022及2024年股權激勵計劃向執行董事授出的股份獎 | | | | | | | 勵和期權 | | | | | | | 變動日期 2026年2月4日 | | | | | | | 於下列日期結束時的結存 (註5及6) 2026年2月4日 | 1,128,128,030 | | 0 | | 1,128,128,030 | | B. 贖回/購回股份 (擬註銷但截至期終結存日期尚未註銷) (註5及6) | | | | | | FF305 第 2 頁 共 6 頁 v 1.3.0 FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 再鼎醫 ...

Group 1 - Morgan Stanley increased its stake in Zai Lab (09688) by acquiring 1,920,096 shares at a price of HKD 13.3426 per share, totaling approximately HKD 25.6191 million [1] - Following the acquisition, Morgan Stanley's total shareholding in Zai Lab reached approximately 56,470,300 shares, representing a stake of 5.04% [1]